LncRNA HSP90AA1-IT1 promotes gliomas by targeting miR-885-5p-CDK2 pathway
Metrics: PDF 2028 views | HTML 2201 views | ?
Taihong Gao1, Guangyan Gu2, Jingxia Tian3, Rui Zhang1, Xiangrong Zheng1, Yanan Wang2, Qi Pang1 and Qian Liu2
1Department of Neurosurgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, China
2Department of Histology and Embryology, Shandong University School of Medicine, Jinan 250012, Shandong, China
3Department of Gynecology and Obstetrics, Jinan Central Hospital Affiliated to Shandong University, Jinan 250013, Shandong, China
Qi Pang, email: [email protected]
Qian Liu, email: [email protected]
Keywords: lncRNA, HSP90AA1-IT1, miR-885-5p, CDK2, glioma
Received: June 08, 2017 Accepted: July 30, 2017 Published: September 08, 2017
It is well established that ncRNAs are emerging as important regulators in various types of cancers, however, their functions and contributions in cancers remain insufficiently defined. In this study, we reported the expression levels of a long noncoding RNA (lncRNA), named HSP90AA1-IT1 (HSP90AA1 intronic transcript 1), appeared to correlate with the pathological grades of gliomas and high level of HSP90AA1-IT1 indicated poor prognosis. Downregulation of HSP90AA1-IT1 in the glioma cell lines significantly suppressed cell viability, proliferation, EMT, invasion and migration in addition to an increase in apoptosis and aberrant cell cycle progression. The tumorigenic capacity of these cells in vivo were also inhibited. We further demonstrated that the oncogenic effects of HSP90AA1-IT1 could be mediated by a direct binding to miR-885-5p. Sharing the same binding sites with CDK2, a key regulator in gliomagenesis, HSP90AA1-IT1 competitively bound to miR-885-5p, thereby prevented CDK2 from miR-885-5p mediated post-transcriptional repression. Taken together, it is concluded that HSP90AA1-IT1, performs its function via regulating the development of gliomas through miR-885-5p-CDK2 signaling axis, and this has added new perspective to its role in tumorigenesis, thus providing potential therapeutic targets for glioma treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.